Clinicopathologic characteristics for the metastatic and nonmetastatic cohorts
| Metastatic (n = 30) | Nonmetastatic (n = 30) | P | ||||
|---|---|---|---|---|---|---|
| Age at diagnosis (y), mean (range) | 53.1 (29-88) | 52.6 (30-81) | NS | |||
| Tumor grade, n (%) | ||||||
| Moderate | 12 (40) | 12 (40) | NS | |||
| Poor | 18 (60) | 18 (60) | NS | |||
| Tumor size (cm), mean (range) | 3.5 (1-11) | 3.7 (1-10) | NS | |||
| Lymph node metastasis, present, n (%) | 20 (67) | 19 (63) | NS | |||
| No. lymph nodes positive, mean (range) | 4.7 (0-17) | 4.3 (0-14) | NS | |||
| Lymphovascular invasion, present, n (%) | 18 (60) | 11 (37) | NS | |||
| Hormone status, n (%) | ||||||
| Estrogen receptor-positive | 19 (63) | 18 (60) | NS | |||
| Progesterone receptor-positive | 11 (37) | 15 (50) | NS | |||
| HER-2/neu overexpression, present, n (%) | 9 (30) | 7 (23) | NS | |||
NOTE: A search of the Cancer Registry database of the New York-Presbyterian Hospital/Weill Cornell Medical Center from 1992 to 2003 yielded 30 patients with known metastatic disease who had undergone primary resection of their breast cancer at New York-Presbyterian Hospital. The same database was then searched to identify a matched nonmetastatic control for each metastatic case. The controls were matched for each of the parameters listed above. There was a minimum follow-up time of 5 y for all cases, and the follow-up time for each control was at least as long as the follow-up time for its metastatic pair.
Abbreviation: NS, not significant; P > 0.05.